Industry: Diagnostics & Research

Sector: Healthcare

Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, the company provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.

Olink Holding AB ADR is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.